AER 1633629 is a spontaneous case, received on 11/Sep/2015 from a physician via Medicines and Healthcare 
Products Regulatory Agency (United Kingdom: GBMHRAADR23136685). It concerns a 71 year old male patient 
who died due to progressive multifocal leucoencephalopathy whilst being treated with rituximab and idelalisib.
Past drugs included  chlorambucil, rituximab, cyclophosphamide, vincristine, prednisolone and fludarabine. 
Concomitant medications included aspirin, finasteride, furosemide, omeprazole, ramipril, simvastatin and 
tamsulosin. No medical history and concurrent conditions were reported. 
On 19/Jan/2015, the patient started therapy with intravenous rituximab 850 mg, every 2 to 4 weeks (form was not 
provided) for chronic lymphocytic leukaemia (CLL) progression. On 22/Jan/2015, he received therapy with oral 
idelalisib 150 mg, twice a day for CLL progression. On 02/Apr/2015, he took most recent dose of rituximab. On 
16/Apr/2015, he developed progressive multifocal leucoencephalopathy which was confirmed with brain biopsy. On 
an unspecified date, therapy with rituximab was interrupted. On 17/Apr/2015, therapy with idelalisib was interrupted.
On (b) (6)  he died due to progressive multifocal leucoencephalopathy. It was unknown if an autopsy was 
performed or not. 
The physician did not report a causality between progressive multifocal leucoencephalopathy and rituximab.
No further information was provided.
This confirmed case of progressive multifocal leukoencephalopathy (PML) is being expedited per 
Roche/Genentech Enhanced Pharmacovigilance Plan for PML.